Abstract
Many clinical observations support the view that immunologic reactions are evoked against malignant melanoma and that these include both circulating antibody and cell-mediated responses, with the latter probably the more important. The evidence from human and animal studies is presented, as are the implications for therapy by such approaches as cross-transplantation of tumors and generalized immunologic stimulation.